Archive

Abstract

The groundbreaking TEMPO 3:4 trial, which served as the basis for tolvaptan's approval, represented a revolution in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Through this advancement, patient management for ADPKD has evolved from using broad strategies to stop the progression of chronic kidney disease to focusing on disease-specific mechanisms. Evidence-based strategies to start treatment only in patients with quickly worsening disease are essential, though, given the long-term nature of this medication and associated side effects. The European Renal Association (ERA) policy statement, released in 2016, was the first society-based guideline on the usage of tolvaptan and has been a popular resource for nephrologists when making decisions. Since then, there has been a significant accumulation of practical knowledge regarding the use of tolvaptan in ADPKD.

Keywords

ADPKD; polycystic kidney disease; position statement; tolvaptan; vasopressin V2 receptor antagonist

Reference

  1. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608.
  2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med. 2007;120(11A):S1–S21. 
  3. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2009. Samsca (tolvaptan), package insert. 
  4. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
  5. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343.
  6. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  7. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112. 
  8. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  9. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  10. Structure of Tolvaptan - https://web.chemdoodle.com/demos/iupac-naming#customise-template
  11. Indian Pharmacopoeia - 2022,  Ninth Edition, Volume – III, Page number: 3832, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, Andhra Pradesh, India.

Photo
Kondeti Venkata Surya Siva Kumar
Corresponding author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Latha Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Jaya Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Kondeti Venkata Surya Siva Kumar, Saripella Latha Sree and Saripella Jaya Sree, Tolvaptan - Vasopressin Antagonist for Hyponatremia, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 8, 1-8. https://doi.org/10.5281/zenodo.8206257

More related articles
Development And Validation Of UV HPLC Method For T...
Amol Amrutkar, Smita Aher, Rishikesh Bachhav, ...
To Formulate And Evaluate Polyherbal Tablet For An...
Pratik D. Dhokare, Pratiksha A. Ingale, Babasaheb L. Chopade, Meg...
Formulation and in vitro evaluation of floating pu...
Sajan Maharjan, Bhaskar Shrestha, Himal Chhetry, Panna Thapa, ...
Aegle Marmelos: A Review Paper ...
Abdul Rahoop Mohamed Riyaz, Thirupathi Jeyalalitha, A. Kuthubu Nisha, A. Amutha, G. Gopalakrishnan, ...
Review on Sublingual Tablets : A Promising Formulation for Instant Action...
Ashish Gupta, T. S. Kanade, S. Mahajan, G. N. Darwhekar, ...
Related Articles
Review Of Monkeypox Virus :Symptoms ,Pathogenesis ,Diagnosis And Treatment...
Pratiksha A. Udawant, Sabafarin Shaikh, Khare Komal, Mayur S. Bhosle, Sushmita Chavan, ...
Exploring The Therapeutic Potential Of Probiotics In Depression: Insights From T...
Mumthas Beegum P. C., Aiswarya Lakshmi P., Amirashirin K.T., E. Tamil Jothi, G. Babu, ...
Formulation And Evaluation of Herbal Kajal...
Sanyukta S. Kute, Sarita L. Sangale, Charushila J. Bhangale, ...
Advancements In Ocular Drug Delivery System: A Comprehensive Review...
Kajal A Choursiya, Shraddha G Kandalkar, Saba R Shaikh, Pradnya K Gangurde, Khanderao R Jadhav , Sac...
More related articles
To Formulate And Evaluate Polyherbal Tablet For Antiurolithatic Activity By Usin...
Pratik D. Dhokare, Pratiksha A. Ingale, Babasaheb L. Chopade, Megha T. Salve, ...
Formulation and in vitro evaluation of floating pulsatile drug delivery system o...
Sajan Maharjan, Bhaskar Shrestha, Himal Chhetry, Panna Thapa, ...
To Formulate And Evaluate Polyherbal Tablet For Antiurolithatic Activity By Usin...
Pratik D. Dhokare, Pratiksha A. Ingale, Babasaheb L. Chopade, Megha T. Salve, ...
Formulation and in vitro evaluation of floating pulsatile drug delivery system o...
Sajan Maharjan, Bhaskar Shrestha, Himal Chhetry, Panna Thapa, ...